| C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma AM Roccaro, A Sacco, C Jimenez, P Maiso, M Moschetta, Y Mishima, ... Blood, The Journal of the American Society of Hematology 123 (26), 4120-4131, 2014 | 224 | 2014 |
| CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation AM Roccaro, Y Mishima, A Sacco, M Moschetta, YT Tai, J Shi, Y Zhang, ... Cell reports 12 (4), 622-635, 2015 | 136 | 2015 |
| Role of endothelial progenitor cells in cancer progression M Moschetta, Y Mishima, I Sahin, S Manier, S Glavey, A Vacca, ... Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1846 (1), 26-39, 2014 | 125 | 2014 |
| The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma SV Glavey, S Manier, A Natoni, A Sacco, M Moschetta, MR Reagan, ... Blood, The Journal of the American Society of Hematology 124 (11), 1765-1776, 2014 | 119 | 2014 |
| Drug delivery approaches for the treatment of cervical cancer F Ordikhani, M Erdem Arslan, R Marcelo, I Sahin, P Grigsby, JK Schwarz, ... Pharmaceutics 8 (3), 23, 2016 | 84 | 2016 |
| Pyk2 promotes tumor progression in multiple myeloma Y Zhang, M Moschetta, D Huynh, YT Tai, Y Zhang, W Zhang, Y Mishima, ... Blood, The Journal of the American Society of Hematology 124 (17), 2675-2686, 2014 | 72 | 2014 |
| Soy isoflavones in integrative oncology: increased efficacy and decreased toxicity of cancer therapy I Sahin, B Bilir, S Ali, K Sahin, O Kucuk Integrative cancer therapies 18, 1534735419835310, 2019 | 69 | 2019 |
| Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses I Sahin, A Eturi, A De Souza, S Pamarthy, F Tavora, FJ Giles, BA Carneiro Cancer Biology & Therapy 20 (8), 1047-1056, 2019 | 67 | 2019 |
| Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma TA Ollila, I Sahin, AJ Olszewski OncoTargets and therapy, 1085-1094, 2019 | 65 | 2019 |
| Targeting vasculogenesis to prevent progression in multiple myeloma M Moschetta, Y Mishima, Y Kawano, S Manier, B Paiva, L Palomera, ... Leukemia 30 (5), 1103-1115, 2016 | 55 | 2016 |
| AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing I Sahin, S Zhang, A Navaraj, L Zhou, D Dizon, H Safran, WS El-Deiry Cell death discovery 6 (1), 57, 2020 | 50 | 2020 |
| CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma AK Azab, I Sahin, F Azab, M Moschetta, Y Mishima, N Burwick, ... Blood, The Journal of the American Society of Hematology 124 (12), 1905-1914, 2014 | 39 | 2014 |
| Temozolomide-related infections: review of the literature MC Kizilarslanoglu, S Aksoy, NO Yildirim, E Ararat, I Sahin, K Altundag J buon 16 (3), 547-550, 2011 | 37 | 2011 |
| Outcomes of locally advanced breast cancer patients with≥ 10 positive axillary lymph nodes E Koca, TY Kuzan, O Dizdar, T Babacan, I Sahin, E Ararat, K Altundag Medical oncology 30, 1-7, 2013 | 35 | 2013 |
| Mechanisms of drug resistance in HCC AD Ladd, S Duarte, I Sahin, A Zarrinpar Hepatology 79 (4), 926-940, 2024 | 31 | 2024 |
| Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia I Sahin N Engl J Med ., 2018 | 25* | 2018 |
| MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection L Zhou, K Huntington, S Zhang, L Carlsen, EY So, C Parker, I Sahin, ... Oncotarget 11 (46), 4201, 2020 | 23 | 2020 |
| The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression AK Azab, E Weisberg, I Sahin, F Liu, R Awwad, F Azab, Q Liu, JD Griffin, ... Leukemia 27 (4), 961-964, 2013 | 23 | 2013 |
| Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphoma AJ Olszewski, AD Chorzalska, M Petersen, TA Ollila, A Zayac, H Kurt, ... Blood advances 5 (24), 5525-5535, 2021 | 21 | 2021 |
| The role of immune checkpoint blockade in the hepatocellular carcinoma: a review of clinical trials M Ozer, A George, SY Goksu, TJ George, I Sahin Frontiers in Oncology 11, 801379, 2021 | 21 | 2021 |
Irene GhobrialDana-Farber Cancer InstituteVerified email at dfci.harvard.edu
